CD59 and acute respiratory distress syndrome: The rationale for ω-3 PUFAs is that they may be beneficial in ARDS as they would compete with ω-6 PUFAs, decrease the synthesis of pro-inflammatory eicosanoids, increase production of anti-inflammatory lipid mediators, such as resolvins and protectins, decrease in chemotaxis, decrease reactive oxygen species (ROS) and pro-inflammatory cytokines, and decrease leukocyte binding and activation through decreased expression of adhesion molecules (Figure 3) (192).